# Multicenter Epidemiological Study for the Evaluation of the Seroprevalence of Total and Neutralizing Antibodies Against Adenoassociated Virus Serotypes Used in Gene Therapy in Patients With Neuromuscular Diseases of Genetic Origin.

> **NCT07633951** · NA · NOT_YET_RECRUITING · sponsor: **Genethon** · enrollment: 450 (estimated)

## Conditions studied

- Neuromuscular Deficits
- Genetic Disorder

## Interventions

- **DIAGNOSTIC_TEST:** Dosage of AAV neutralizing antibodies

## Key facts

- **NCT ID:** NCT07633951
- **Lead sponsor:** Genethon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633951, "Multicenter Epidemiological Study for the Evaluation of the Seroprevalence of Total and Neutralizing Antibodies Against Adenoassociated Virus Serotypes Used in Gene Therapy in Patients With Neuromuscular Diseases of Genetic Origin.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*